Alpha 1 Antitrypsin Deficiency Treatment Market is Estimated to Reach a Valuation of US$2,908.1 mn by the end of 2025

Press Release

Global Alpha-1 Antitrypsin Deficiency Treatment Market: Snapshot

The demand in the global alpha-1 antitrypsin deficiency treatment market is projected to increment at an admirable CAGR of 10.3% during the forecast period of 2017 to 2025, gaining traction from a number of factors such as improvements in the diagnostics of alpha-1 antitrypsin deficiency, improving economic scenario in various emerging economies, ample of opportunities in the development of new products, and high unmet demand across the globe. On the other hand, stringent regulations, high cost of drugs, and limited plasma fractionation capacity are some of the hindrances faced by the market, and until these are overcome, the prosper prosperity will not be achieved.

Obtain Report Details @

The global alpha-1 antitrypsin deficiency treatment market is estimated to reach a valuation of US$2,908.1 mn by the end of 2025, notably up from its evaluated worth of US$1,224.5 mn in 2016. The stockholders of the global alpha-1 antitrypsin deficiency treatment market are expected to gain new opportunities in the near future via strategic alliances and growing awareness regarding this deficiency disease.

Request for Sample Copy of Report @

Augmentation Therapy Profitable Treatment Segment

On the basis of treatment type, the global alpha-1 antitrypsin deficiency treatment market is segmented into augmentation therapy, bronchodilator, corticosteroids, and oxygen therapy. The segment of augmentation therapy, which is further sub-segmented into aralast, prolastin, glassia, and zemaira or respreeza, currently serves the maximum demand in the global alpha-1 antitrypsin deficiency treatment market, and is expected to sustain its position by the end of 2025, followed by bronchodilator treatment segment. Based on end-user, the AATD market gains maximum demand from hospitals, although specialty clinics are projected for most prominent growth rate. This report also segments the alpha-1 antitrypsin deficiency treatment market on the basis of route of administration, into inhalations, parenteral, and oral, and rates parenteral segment as the most profitable route of administration, which is a reflection of benefits such as ease of drug administration and high chances of avoiding first-pass metabolism.

Request Report Brochure @

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: [email protected]


Related Articles